Please folks, the DSMB's job was only to look to see if the trial had any bad effects on patients and if they did, they would stop the trial immediately. Their job was just to look into the trial and they did and determined that the trial is proceeding fine with no adverse effects on patients. They didn't even ask for any modifications to the trial so everything is going well and again, that is all that board was meant to do as the trial protocol was designed for this at the very beginning of the trial.

Don't let anyone tell you differently for they weren't peaking for efficacy or how well the participants were doing, NOTHING but a looksee.

Kabonk, please look at the trial design again and don't be feared by anyone unless you allow yourself to be feared. GLTU and welcome to the board

HCIT

Your quote: They should have looked at the totality of all the safety data / adverse events, including deaths, but also probably things like going on ECMO or stroke or heart/liver/kidney failure, and other serious adverse events in both groups.

Read More: https://investorshangout.com/post/newpost/605...z6UFi9K1hp